Multiple sclerosis

By Mayo Clinic Staff
Nov. 01, 2024

Research

Mayo Clinic researchers are working to improve the diagnosis and treatment of multiple sclerosis. Specific efforts include finding causes of the disease and developing strategies for remyelination and axonal repair.

Read more about research in the Mayo Clinic Laboratories and in the Center for Multiple Sclerosis and Autoimmune Neurology.

Publications

See a list of publications by Mayo Clinic doctors on multiple sclerosis on PubMed, a service of the National Library of Medicine.

  1. What is multiple sclerosis? National Multiple Sclerosis Society. https://www.nationalmssociety.org/What-is-MS. Accessed June 10, 2024.
  2. Clinical overview: Multiple sclerosis. Elsevier Point of Care. 2023. https://www.clinicalkey.com. Accessed June 19, 2024.
  3. Olek MJ, et al. Clinical presentation, course, and prognosis of multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
  4. Olek MJ, et al. Pathogenesis and epidemiology of multiple sclerosis. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
  5. Olek MJ, et al. Evaluation and diagnosis of multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
  6. Olek MJ, et al. Treatment of acute exacerbations of multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
  7. Olek MJ, et al. Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
  8. Olek MJ, et al. Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
  9. Olek MJ, et al. Clinical use of oral disease-modifying therapies for multiple sclerosis. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
  10. Olek MJ, et al. Symptom management of multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
  11. Olek MJ, et al. Overview of disease-modifying therapies for multiple sclerosis. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
  12. Olek MJ, et al. Manifestations of multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
  13. Jankovic J, et al., eds. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. In: Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed June 19, 2024.
  14. Pizzorno JE, et al., eds. Multiple sclerosis. In: Textbook of Natural Medicine. 5th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed June 19, 2024.
  15. Krämer J, et al. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nature Reviews Neurology. 2023; doi:10.1038/s41582-023-00800-7.
  16. Pediatric MS. National Multiple Sclerosis Society. https://www.nationalmssociety.org/for-professionals/for-healthcare-professionals/managing-and-treating-ms/pediatric-ms. Accessed June 19, 2024.
  17. Multiple sclerosis. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/multiple-sclerosis#. Accessed June 24, 2024.
  18. Saadeh RS, et al. CSF kappa free light chains: Cutoff validation for diagnosing multiple sclerosis. Mayo Clinic Proceedings. 2022; doi:10.1016/j.mayocp.2021.09.014.
  19. Nimmagadda R. Allscripts EPSi. Mayo Clinic. May 13, 2024.
  20. Deb C. CD8+ T cells cause disability and axon loss in a mouse model of multiple sclerosis. PLOS One. 2010; doi:101371/journal.pone.0012478.
  21. Fadul CE, et al. Safety and immune effects of blocking CD40 ligand in multiple sclerosis. Neurology Journals. 2021; doi:10.1212/NXI.0000000000001096.
  22. Nakamura K, et al. Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis. Multiple Sclerosis Journal. 2024; doi:10.1177/13524585231224702.
  23. Katz Sand I, et al. Mediterranean diet is linked to less objective disability in multiple sclerosis. Multiple Sclerosis Journal. 2023; doi:10.1177/13524585221127414.
  24. Kantarci OH, et al. Novel immunomodulatory approaches for the management of multiple sclerosis. Clinical Pharmacology & Therapeutics. 2014; doi:10.1038/clpt.2013.196.
  25. Winn HR, ed. Neuropsychological testing. In: Youmans and Winn Neurological Surgery. 8th ed. Elsevier; 2023. https://www.clinicalkey.com. Accessed Oct. 21, 2024.
  26. Hancock LM, et al. Neuropsychological manifestations of multiple sclerosis. Neurologic Clinics. 2024; doi:10.1016/j.ncl.2024.05.010.